Navigation Links
deCODE Genetics Announces Full-year 2007 Financial Results

REYKJAVIK, ICELAND, March 12 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter and year ended December 31, 2007. A conference call to discuss the year's results and operating highlights will be webcast live tomorrow, Thursday, March 13, at 8:00am EDT/12 noon GMT (details below).

Net loss for the year ended December 31, 2007 was $95.5 million, compared to $85.5 million for the full year 2006. Basic and diluted net loss per share was $1.57 for the full year 2007, compared to $1.49 for the full year 2006. At the close of 2007, the company had approximately 61.7 million shares outstanding.

Revenue for the year ended December 31, 2007 was $40.4 million, versus $40.5 million for the full year 2006. At December 31, 2007, the company had $15.4 million in deferred revenue, which will be recognized over future reporting periods.

Research and development expense for proprietary programs was $53.8 million for the full year 2007, compared to $57.1 million for the full year 2006. Selling, general and administrative expenses for the full year 2007 were $27.1 million, compared to $25.2 million for 2006.

At December 31, 2007, the company had $94.1 million in cash and cash equivalents, restricted cash equivalents and current and non-current investments, compared to $152.0 million at December 31, 2006. As discussed below, the year end 2007 figure includes temporary and other-than-temporary impairment charges resulting from an independent, third-party estimate of the current value of certain auction-rate securities (ARS) held by the company.

"Over the past year we have made steady progress in both our near-term and long-term strategy to capitalize on our leadership in human genetics. We have brought to market pioneering DNA-based risk assessment tests for type 2 diabetes, early-onset heart attack, atrial fibrillation/stroke, prostate cancer, and glaucoma, and launched the world's first personal genome analysis service, deCODEme(TM). With these diagnostics and personal genome products on the market, and others to be launched in the months ahead, deCODE is focused on capturing the potential of our competitive advantage in human genetics, at the same time as we seek partnerships to advance our therapeutics programs and to most efficiently allocate spending and spread risk. We are committed to executing on this strategy and to ensuring we have the cash resources to maximize the creation of value for the company and its shareholders," said Kari Stefansson, CEO of deCODE.

Fourth quarter 2007 results

Revenue for the quarter ended December 31, 2007 was $13.3 million, compared to $11.5 million for the fourth quarter 2006. Net loss for the fourth quarter 2007 was $32.4 million, compared to $23.2 million for the same period a year ago. $7.8 million of the fourth quarter net loss figure is due to ARS- related impairment charges. Research and development expense for proprietary programs decreased to $12.6 million for the fourth quarter 2007 from $14.2 million for the same period in 2006. For the fourth quarter 2007, selling, general and administrative expenses were $7.7 million versus $8.6 million for the fourth quarter 2006.

Key highlights over the past year include:

Product Development

-- Diagnostics. Over the past year deCODE has brought to market its first

DNA-based reference laboratory diagnostic tests for gauging risk of

several major diseases. These pioneering tests are based upon deCODE's

discoveries of major genetic risk factors for many of the major

challenges to public health, and provide a new means for assessing

individual risk and optimizing measures to prevent these diseases.

deCODE's growing list of tests include deCODE T2(TM), for assessing

inherited risk of type 2 diabetes; deCODE AF(TM), for assessing risk of

atrial fibrillation, a common precursor of stroke; deCODE MI(TM), a

test for a major genetic risk factor for early-onset heart attack as

well as abdominal aortic and intracranial aneurysms; deCODE ProCa(TM),

which detects several significant genetic risk variants for prostate

cancer; and we have recently completed work on a test for assessing

inherited risk of a major type of glaucoma.

-- deCODEme(TM). Bringing together deCODE's leadership in human genetics

and recent advances in genotyping technology, in November 2007 deCODE

launched the first personal genome analysis service: deCODEme(TM). The

service takes advantage of deCODE's leadership in human genetics and

its whole-genome genotyping capabilities. Through deCODEme(TM),

subscribers can put themselves in the context of the latest discoveries

in genetics, learning what their own DNA says about their ancestry,

certain physical traits, as well as whether they have genetic variants

that have been associated with higher or lower than average risk of a

range of common diseases. This information is continually updated as

new discoveries are made, and is presented in the subscriber's secure

individual web page.

-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class

antagonist of the EP3 receptor for prostaglandins E2, being developed

as a next-generation oral anti-platelet therapy for preventing arterial

thrombosis without increasing bleeding time. In a Phase II clinical

trial and additional clinical pharmacology studies completed in 2007,

DG041 was shown to dramatically inhibit platelet aggregation as well as

platelet activation mediated specifically through vasodilator

stimulated phosphoprotein (VASP), a biomarker useful for measuring

platelet activity. These effects were concentration-dependent and were

seen irrespective of whether patients were receiving concomitant

therapy with aspirin. The company is building upon these successful

results with a second clinical pharmacology study of the effects of

DG041 when taken with aspirin and Plavix(TM). deCODE is also working on

a once-daily formulation for DG041.

-- Heart attack: DG051 & DG031. In 2007 deCODE completed Phase I and phase

IIa clinical testing of DG051, the company's developmental compound for

the prevention of heart attack. DG051, discovered by deCODE chemists,

is designed to counter risk of heart attack by reining in the activity

of the leukotriene pathway, reducing the production of leukotriene B4

(LTB4). LTB4 is a pro-inflammatory molecule that deCODE's gene

discovery and functional biology work identified as a one of the

factors modulating risk of heart attack. deCODE's clinical studies to

date have showed DG051 to reduce LTB4 production in a dose-dependent

manner, even in cardiovascular patients taking concomitant medications.

deCODE has also completed the reformulation of DG031, its other

compound targeting the leukotriene pathway for the prevention of heart

attack, and is actively seeking a partner with whom to take the next

step in development of its leukotriene program.

Target Discovery

-- deCODE has continued to lead the world in the discovery of common

genetic variants linked to significantly increased risk of common

diseases. Since the beginning of 2007, deCODE has discovered novel

variants conferring risk of type 2 diabetes, prostate cancer, early

onset heart attack, breast cancer, atrial fibrillation and stroke,

restless leg syndrome, glaucoma, and two types of aneurysm. The company

has also used its unique capabilities in human genetics to make

breakthrough discoveries shedding light on human evolution, fertility,

and pigmentation.

Cash position and ARS

-- At December 31, 2007 the company held investments in ARS with original

purchase principal values totalling $38.5 million. As part of deCODE's

cash management program and in line with its treasury policy, the

company had invested in investment-grade ARS. These securities are

private placement securities with long-term nominal maturities, for

which the interest rates have historically been reset through active

monthly auctions. Recent uncertainties in the credit markets have

prevented us and other investors from liquidating holdings of our

remaining ARS in recent auctions because the amount of securities

submitted for sale has exceeded the amount of purchase orders. As

liquidity will be limited until there is a successful auction or until

such time as other markets for these ARS investments develop, the

company has classified as non-current investments totalling $33.5

million of the company's ARS holdings previously reported as current

assets on our December 31, 2007 balance sheet. Based upon an

independent, third-party valuation, the estimated market value of our

non-current investments in ARS at December 31, 2007 amounted to $24.8

million. This is an $8.7 million adjustment to the principal value of

$33.5 million, of which we believe $0.9 million is temporary. Although

the ARS held by deCODE are still investment-grade and continue to pay

interest according to their stated terms, after an analysis of other

than-temporary impairment factors we have recorded an impairment charge

of $7.8 million for the year ended December 31, 2007. This charge is

included in Other Income (Expense) in our Statements of Operations, net

principally against payments received as part of the favourable

settlement of the intellectual property suit filed by deCODE in 2006.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at; on our diagnostics website at; and, for our pioneering personal genome analysis service, at

Conference Call Information

A conference call, during which deCODE President and CEO Kari Stefansson and CFO Lance Thibault will discuss the past year's financial results and operating highlights, will be webcast tomorrow, Thursday, March 13, at 8:00am EDT/12 noon GMT. The webcast can be accessed via the Investors section of deCODE's website,, or through A replay of the call will be available on these websites for at least one week following the call. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1 800 475 6701 from the US, or +1 320 365 3844 from outside the US. The access code is 914354.

Condensed Consolidated Statements of Operations

For the three months For the full-year

ended December 31, ended December 31,

2007 2006 2007 2006

in thousands, except per share amounts (unaudited)

Revenue $13,343 $11,451 $40,403 $40,510


Cost of revenue 14,968 10,994 47,018 42,660

Research and development 12,552 14,206 53,825 57,108

Selling, general and

administrative 7,744 8,609 27,139 25,206

Total operating expense 35,264 33,809 127,982 124,974

Operating loss (21,921) (22,358) (87,579) (84,464)

Interest income 1,386 1,803 6,541 6,685

Interest expense (4,153) (2,673) (15,641) (7,808)

Other non-operating income

and (expense), net (7,737) 3 1,153 114

Net loss $(32,425) $(23,225) $(95,526) $(85,473)

Basic and diluted net loss

per share: $(0.53) $(0.38) $(1.57) $(1.49)

Shares used in computing

basic and diluted net

loss per share 61,085 60,826 61,018 57,465

Condensed Consolidated Balance Sheet Data

At December 31, At December 31,

2007 2006

in thousands (unaudited)

Cash and investments* $94,058 $152,016


assets 156,208 215,609


liabilities 301,858 270,988

Total shareholders'

equity (145,650) (55,379)

* cash and investments include cash equivalents, restricted cash

equivalents and current and non-current investments

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


deCODE genetics

Joy Bessenger Berglind Olafsdottir Edward Farmer

+354 570 1900 +354 570 1900 +1 212 343 2819

+1 (212) 481 3891

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology:
(Date:8/23/2017)... N.Y. , Aug. 23, 2017  The general public,s help is ... human microbiome—the bacteria that live in and on the human body –and ... The ... in the human microbiome, starting with the gut. The project's goal is ... disease. Photo credit: IBM ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
Breaking Biology News(10 mins):